Clinical Scorecard: Reduced Diversity of Antimicrobial Resistance Genes After Administration of Fecal Microbiota, Live-jslm (REBYOTA®): A Post Hoc Evaluation of PUNCH CD3
Restoration of gut microbiome diversity and colonization resistance via fecal microbiota transplantation reduces antimicrobial resistance gene richness
Target Population
Patients with recurrent Clostridioides difficile infection following standard-of-care antibiotic treatment
Care Setting
Healthcare settings managing recurrent CDI and microbiome-based therapeutic interventions
Key Highlights
RBL (REBYOTA) administration significantly reduces antimicrobial resistance gene (ARG) richness compared to placebo in rCDI patients.
ARG richness reduction is evident as early as 1 week post-treatment and sustained for at least 6 months.
RBL responders show decreased abundance of high-risk ARGs linked to critical public health bacterial threats.
Guideline-Based Recommendations
Diagnosis
Use metagenomic sequencing of fecal samples to assess antimicrobial resistance gene richness as a marker of colonization resistance.
Management
Administer fecal microbiota, live-jslm (REBYOTA) following standard-of-care antibiotics to prevent recurrent CDI and reduce ARG richness.
Consider microbiota-based therapies to restore gut microbial diversity and reduce colonization by antibiotic-resistant organisms.
Monitoring & Follow-up
Monitor patients post-RBL treatment for sustained reduction in antimicrobial resistance gene richness up to 6 months.
Assess clinical response defined by absence of CDI diarrhea through 8 weeks post-treatment.
Risks
Recognize that standard antibiotic treatments for CDI may prolong microbiome disruption and increase risk of ARG colonization.
Be aware of potential colonization by opportunistic antibiotic-resistant organisms in patients with disrupted microbiomes.
Patient & Prescribing Data
Adults with recurrent Clostridioides difficile infection after antibiotic therapy
RBL treatment achieved a 70.6% success rate in preventing rCDI compared to 57.5% with placebo, with associated reductions in antimicrobial resistance gene richness.
Clinical Best Practices
Incorporate microbiota-based products like RBL to break the cycle of CDI recurrence by restoring colonization resistance.
Utilize metagenomic sequencing to evaluate microbiome health and antimicrobial resistance gene profiles in clinical trials and potentially in clinical practice.
Recognize the importance of maintaining gut microbiome diversity to prevent colonization by multidrug-resistant organisms.
